MRCG.DE
Latest Trade
148.90EURChange
-0.80(-0.53%)Volume
355,189Today's Range
-
149.8052 Week Range
-
149.95As of on the XETRA ∙ Minimum 15 minute delay
Previous Close | 149.70 |
|---|---|
Open | 149.05 |
Volume | 355,189 |
3M AVG Volume | 9.73 |
Today's High | 149.80 |
Today's Low | 147.95 |
52 Week High | 149.95 |
52 Week Low | 76.22 |
Shares Out (MIL) | 434.78 |
Market Cap (MIL) | 19,244.17 |
Forward P/E | 22.37 |
Dividend (Yield %) | 0.87 |
Merck Buys Hamburg-Based AmpTec
Merck Expands Life Science Production Capacities In The United States
Artios And Merck KGaA Announce Global Strategic Collaboration
Merck KGaA is a Germany-based science and technology company. The Company operates in three business segments: Healthcare, Life Sciences and Performance Materials. The Healthcare business, which operates in the United States and Canada as EMD Serono, focuses on such therapeutic areas as allergies, fertility, oncology and neurodegenerative diseases, developing drugs, diagnostic substances and medical devices. The Life Sciences business comprises the activities of MilliporeSigma, which provides solutions that facilitate biotechnology and pharmaceutical research. The product range includes laboratory water systems, gene editing tools, cell lines and end-to-end drug manufacturing systems, among others. The Performance Materials business provides specialty chemicals for various applications, including liquid crystals for electronic displays, materials for integrated circuits, effect pigments for coatings and color cosmetics, as well as functional materials for energy solutions.
Industry
Major Drugs
Executive Leadership
Wolfgang Buechele
Independent Chairman of the Supervisory Board
Stefan Oschmann
Chairman of the Executive Board and Chief Executive Officer
Michael Fletterich
Independent Vice Chairman of the Supervisory Board, Employee Representative
Marcus Kuhnert
Member of the Executive Board, Chief Financial Officer
Udit Batra
Chief Executive Officer Life Science, Member of the Executive Board
Price To Earnings (TTM) | 34.38 |
|---|---|
Price To Sales (TTM) | 1.11 |
Price To Book (MRQ) | 3.69 |
Price To Cash Flow (TTM) | 5.18 |
Total Debt To Equity (MRQ) | 76.19 |
LT Debt To Equity (MRQ) | 55.65 |
Return on Investment (TTM) | 5.74 |
Return on Equity (TTM) | 4.43 |
Germany's Merck KGaA said on Thursday it has agreed a three-year strategic research deal worth up to $6.8 billion with Artios Pharma Limited to develop up to eight potential drugs for cancer by targeting DNA repair mechanisms inside cells.
Germany's Merck KGaA said on Thursday it has signed a three-year strategic research deal with Artios Pharma Limited to discover and develop up to eight potential targeted treatments for cancer.
Healthcare and chemicals group Merck KGaA <MRCG.DE> lifted its guidance for full year earnings after the scramble to ready treatments and vaccines against the coronavirus bolstered demand for its supplies for biotech labs.
Healthcare and chemicals group Merck KGaA lifted its guidance range for full year earnings, citing strong sales of new drugs, biotech supplies and equipment as well as semiconductor materials during the third quarter.
Note: This story has been corrected to name Merck KGaA, not Merck & Co, in the first paragraph.
* Life Science unit has invested more than 425 mln eur since 2017
German drugs and chemicals maker Merck KGaA <MRCG.DE> said on Wednesday it would until 2022 focus on cutting its debt from the takeover of electronic materials company Versum and any acquisitions thereafter would likely be smaller ones.
Merck KGaA <MRCG.DE> on Thursday was more upbeat about its worst-case scenario for full-year earnings, as patients previously deterred by lockdown measures begin to seek the company's treatments again.
Merck KGaA on Thursday was more upbeat about its worst-case scenario for full-year earnings, as patients previously deterred by lockdown measures begin to seek the company's treatments again.
* MERCK KGAA, DARMSTADT, GERMANY ANNOUNCES OPENING OF ITS LIFE SCIENCE BUSINESS' LARGEST M LAB™ COLLABORATION CENTER IN SHANGHAI Source text for Eikon: Further company coverage: (Berlin Speed Desk)
The European Commission has struck deals with drugmakers Roche <ROG.S> and Merck KGaA <MRCG.DE> to secure supplies of experimental treatments for COVID-19, a Commission source told Reuters on Wednesday.
The European Commission has reached agreements with pharmaceutical companies Roche and Merck KGaA to supply experimental drugs that can be used to treat COVID-19 patients, a commission source told Reuters on Wednesday.
The European Commission has reached agreements with pharmaceutical companies Roche and Merck KGaA to supply experimental drugs that can be used to treat COVID-19 patients, a commission source told Reuters on Wednesday.
U.S. drugmaker Sigma-Aldrich provided incorrect and misleading information during an antitrust review of its 2015 takeover by Merck KGaA <MRCG.DE>, EU regulators said on Wednesday as they dropped the German company from their investigation.
* RECEIVES EU COMMISSION SUPPLEMENTARY STATEMENT OF OBJECTIONS IN THE PROCEEDINGS CONCERNING THE SIGMA-ALDRICH ACQUISITION
* INITIATES FIRST CLINICAL TRIAL OF TLR7 AND 8 INHIBITOR AS A POTENTIAL TREATMENT FOR SEVERE SYMPTOMS OF COVID-19 INFECTION
* MERCK KGAA - EUROPEAN MEDICINES AGENCY VALIDATES APPLICATION FOR BAVENCIO® (AVELUMAB) FOR FIRST-LINE MAINTENANCE TREATMENT OF LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA
* SIGNED CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH MERCK KGAA
* MERCK AND BAYLOR COLLEGE OF MEDICINE COLLABORATE TO ADVANCE A VACCINE MANUFACTURING PLATFORM TO FIGHT COVID-19
* WE WILL RAISE LIQUIDITY RESERVES TO ABOUT 3 BLN EURO TO BE PREPARED FOR ANYTHING - CFO
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.